| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 新大洲A | 000571 | 股权激励限售流通 | 980.75万 | | 中钨高新 | 000657 | 股权激励限售流通 | 72.06万 | | 东方钽业 | 000962 | 股权激励限售流通 | 156.87万 | | 内蒙一机 | 600967 | 股权激励限售流通 | 663.31万 | | 三花智控 | 002050 | 股权激励限售流通 | 701.47万 | | 大禹节水 | 300021 | 股权激励限售流通 | 76.17万 | | 瑞普生物 | 300119 | 股权激励限售流通 | 69.76万 | | 海南矿业 | 601969 | 股权激励限售流通 | 364.05万 | | 吉翔股份 | 603399 | 股权激励限售流通 | 309万 | | 华电重工 | 601226 | 股权激励限售流通 | 388.82万 | | 星徽股份 | 300464 | 股权激励限售流通 | 576万 | | 博济医药 | 300404 | 股权激励限售流通 | 20万 | ...

证券代码：301108 证券简称：洁雅股份 公告编号：2025-030 铜陵洁雅生物科技股份有限公司 关于部分首次公开发行前已发行股份上市流通提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、铜陵洁雅生物科技股份有限公司（以下简称"公司"或"发行人"）本 次解除限售的股份为公司首次公开发行前已发行的部分股份。 2、本次申请解除限售股东户数共计6户，解除限售股份数量为45,717,710股， 占公司总股本的56.8647%，实际上市流通股份数量为11,758,308股，占公司总股本 的14.6252%。 3、本次解除限售股份可上市流通日为2025年6月4日（星期三）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意铜陵洁雅生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2021]3365 号）同意注册，并经深圳证券 交易所同意，公司首次公开发行人民币普通股（A 股）股票 20,302,458 股，并于 2021 年 12 月 3 日在深圳证券交易所创业板上市交易。公司首次公开发行前总股 本为 60,9 ...

国融证券股份有限公司 关于铜陵洁雅生物科技股份有限公司 部分首次公开发行前已发行股份上市流通的核查意见 国融证券股份有限公司（以下简称"国融证券"或"保荐机构"）作为铜陵 洁雅生物科技股份有限公司（以下简称"公司""发行人"或"洁雅股份"）首 次公开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第2号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管 指引第13号——保荐业务》等相关规定，对洁雅股份部分首次公开发行前已发行 股份上市流通事项进行了核查，核查情况如下： 一、首次公开发行前已发行股份情况 经中国证券监督管理委员会《关于同意铜陵洁雅生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2021]3365 号）同意注册，并经深圳证券 交易所同意，公司首次公开发行人民币普通股（A 股）股票 20,302,458 股，并于 2021 年 12 月 3 日在深圳证券交易所创业板上市交易。公司首次公开发行前总股 本为 60,907,360 股，首次公开发行后总股本为 81,209,818 股， ...

Company Overview - Tongling Jieya Biotechnology Co., Ltd. was established in 1999 and specializes in the research, production, and sales of wet wipes, with over 20 years of industry experience [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2]. - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 10.06 million yuan [2]. Q&A Highlights - **Impact of Tariffs**: The current tariff policies have a relatively limited impact on the company's overall business [3]. - **US Wet Wipe Factory Project**: The project is currently under construction and is expected to commence production next year [3]. - **Kimberly-Clark European Orders**: Production began in April 2025, and order deliveries are progressing as planned [3]. - **Asset Impairment**: The company adheres to accounting standards and will reasonably assess asset impairment based on prudence [3]. - **Self-Branding Considerations**: The company is exploring self-branding through an industrial fund but has seen low revenue conversion rates [3]. - **Facial Mask Business Outlook**: Currently serving major clients like L'Oréal and Galen Group, with a gradual expansion to other domestic brands, though new client orders are relatively small [3]. - **Jiechuang Medical Subsidiary**: The subsidiary is undergoing strategic adjustments, with cautious investment based on overall business layout and resource optimization [3]. - **Equity Incentives**: The company is focused on establishing long-term incentive mechanisms and will disclose plans as they develop [3]. - **Compliance with Regulations**: The company conducted the investor communication event in accordance with regulatory guidelines, ensuring no undisclosed significant information leaks occurred [3].

Group 1 - The recombinant protein concept sector rose by 2.52%, ranking second among concept sectors, with 30 stocks increasing in value [1][2] - Notable gainers included Sangon Biotech, which hit the daily limit with a 20% increase, and other significant performers such as Sai Sheng Pharmaceutical, Jie Ya Co., and Jinbo Bio, which rose by 16.37%, 9.31%, and 9.17% respectively [1][2] - The sector experienced a net inflow of 221 million yuan from main funds, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Leading the net inflow was Xilong Scientific, which saw a net inflow of 242 million yuan, followed by Rejuve Pharmaceutical and Zexin Pharmaceutical with net inflows of 37.78 million yuan and 32.48 million yuan respectively [2][3] - The top three stocks by net inflow ratio were Xilong Scientific at 20.85%, Zexin Pharmaceutical at 8.53%, and Chengdu Xian Dao at 7.96% [3][4] - Stocks with notable declines included Furuida, Zhongyuan Xiehe, and Wanmei Biological, which fell by 2.25%, 1.92%, and 1.80% respectively [1][5]

Company Overview - Tongling Jeya Biotechnology Co., Ltd. was established in 1999 and specializes in the research, production, and sales of wet wipes, accumulating over 20 years of industry experience [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2]. Financial Performance - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 10.06 million yuan [2]. Q&A Highlights - **Impact of Tariff Policies**: Current tariff adjustments have not significantly affected the company's operations, and the overall impact is manageable [3]. - **U.S. Production Base**: The construction of the U.S. production base is progressing as planned, currently in the foundational construction phase, with production expected to commence in 2025 [3]. - **Performance Trends**: The company has stabilized its performance through business restructuring and successfully acquired Kimberly-Clark's European business [3]. - **Personal Care Business Development**: The personal care segment primarily focuses on OEM for L'Oréal, with plans to expand domestic clientele, although current order volumes are small. Future growth may involve industry acquisitions [3]. - **Strategic Development Direction**: The company aims to deepen existing business operations while exploring innovative fields such as biosynthesis technology and core materials for the health industry [3]. - **Own Brand Consideration**: The company has initiated incubation trials through an industrial fund, focusing on online marketing, though market conversion rates have not met expectations [3]. - **Customer Dependency Risks**: The company collaborates with well-known global enterprises, ensuring stable partnerships. Major clients have stringent quality requirements and established supplier certification systems, making supplier changes infrequent. The company plans to optimize its business structure and enhance core competitiveness through technological innovation [3]. Compliance and Regulations - The investor communication event adhered strictly to the Shenzhen Stock Exchange's self-regulatory guidelines, ensuring no significant undisclosed information was leaked [3].

证券代码：301108 证券简称：洁雅股份 公告编号：2025-029 铜陵洁雅生物科技股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）下午 14:00。 （2）网络投票时间：2025 年 5 月 16 日（星期五）。 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 16 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的时 间为：2025 年 5 月 16 日 9:15-15:00。 2、会议召开地点：安徽省铜陵市狮子山经济开发区铜井东路 1928 号铜陵洁 雅生物科技股份有限公司会议室。 3、会议召开方式：采取现场表决与网络投票相结合的方式召开。 4、会议召集人：公司董 ...

天禾律师 股东会法律意见书 根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共和 国证券法》（下称"《证券法》"）、中国证券监督管理委员会《上市公司股东 会规则》（下称"《股东会规则》"）以及《铜陵洁雅生物科技股份有限公司章 程》（下称"《公司章程》"）的有关规定，安徽天禾律师事务所接受铜陵洁雅 生物科技股份有限公司（下称"公司"）委托，指派冉合庆、席彤彤律师（下称 "天禾律师"）出席公司 2024 年度股东大会（下称"本次股东会"），并对本 次股东会相关事项进行见证，出具法律意见。 2024 年度股东大会法律意见书 安徽天禾律师事务所 天律意 2025 第 01153 号 致：铜陵洁雅生物科技股份有限公司 关于铜陵洁雅生物科技股份有限公司 本法律意见书是天禾律师根据对本次股东会事实的了解及对我国现行法律、 法规和规范性文件的理解而出具的。 天禾律师同意将本法律意见书作为本次股东会的法定必备文件予以公告，并 依法对所出具的法律意见书承担责任。 天禾律师根据《证券法》相关规定的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对本次股东会的召集、召开、与会人员资格、表决程 序及其他相关法 ...

Market Overview - A-shares experienced a downward trend, with the Shanghai Composite Index closing at 3380.82, down 0.68%, and the Shenzhen Component Index down 1.62% at 10186.45 [1] - The Hong Kong market also declined, with the Hang Seng Index falling nearly 1% and the Hang Seng Tech Index down 1.5% [1] Consumer Sector Performance - The consumer sector showed strong performance, particularly in beauty and personal care, which rose by 6.46%, with 31 out of 33 stocks increasing [2] - The cosmetics segment led the A-share market with no stocks declining, and significant gains were noted for companies like Bawei Co. and Qingsong Co. [2] - Retail sales in the cosmetics sector are projected to reach 114.9 billion yuan by Q1 2025, reflecting a 3.20% year-on-year growth [2] Promotional Activities and Market Dynamics - Major platforms like Tmall, Douyin, and JD.com are intensifying competition with synchronized promotional events starting on May 13 [3] - The beauty and personal care sector is expected to see structural opportunities due to extended promotional periods and product innovation [3] - The apparel sector also showed activity, with companies like Anzheng Fashion hitting the daily limit [3] Synthetic Biology Sector - The synthetic biology concept saw a rise, particularly after a promotional campaign by Kelun Pharmaceutical, which boosted interest in the sector [4] - The synthetic biology sector's overall increase was 2.05%, with several stocks achieving significant gains [4] - The demand for bio-based materials and pharmaceutical intermediates is expected to grow, providing a broad market for synthetic biology companies [5] Shipping and Port Sector - The shipping sector saw a resurgence, with the European shipping index rising by 8.72% [7] - Companies like China National Offshore Oil Corporation and Ningbo Port experienced significant stock price increases, with some stocks hitting the daily limit [7] - Recent adjustments in U.S.-China tariff policies have led to a surge in exports to the U.S., boosting shipping volumes [7][8]

（原标题：美容护理行业5月15日资金流向日报） 沪指5月15日下跌0.68%，申万所属行业中，今日上涨的有4个，涨幅居前的行业为美容护理、煤炭，涨 幅分别为3.68%、0.42%。美容护理行业位居今日涨幅榜首位。跌幅居前的行业为计算机、通信，跌幅 分别为2.97%、2.45%。 美容护理行业今日上涨3.68%，全天主力资金净流入3.86亿元，该行业所属的个股共31只，今日上涨的 有28只，涨停的有8只；下跌的有3只。以资金流向数据进行统计，该行业资金净流入的个股有23只，其 中，净流入资金超3000万元的有9只，净流入资金居首的是福瑞达，今日净流入资金1.11亿元，紧随其 后的是青松股份、洁雅股份，净流入资金分别为6854.51万元、4824.24万元。美容护理行业资金净流出 个股中，净流出资金居前的有青岛金王、稳健医疗、上海家化，净流出资金分别为1.72亿元、1446.11万 元、1146.58万元。（数据宝） | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600223 | 福瑞达 | 10. ...